• Lane M Smith, Graciela B Mentz, and Milo C Engoren.
• Department of Anesthesiology, Section of Critical Care, University of Michigan, Ann Arbor, MI.
• Crit. Care Med. 2023 Dec 1; 51 (12): 167416841674-1684.

ObjectivesTo determine if angiotensin II is associated with improved outcomes as measured by 30- and 90-day mortality as well as other secondary outcomes such as organ dysfunction and adverse events.DesignRetrospective, matched analysis of patients receiving angiotensin II compared with both historical and concurrent controls receiving equivalent doses of nonangiotensin II vasopressors.SettingMultiple ICUs in a large, university-based hospital.PatientsEight hundred thirteen adult patients with shock admitted to an ICU and requiring vasopressor support.InterventionsNone.Measurements And Main ResultsAngiotensin II use had no association with the primary outcome of 30-day mortality (60% vs 56%; p = 0.292). The secondary outcome of 90-day mortality was also similar (65% vs 63%; p = 0.440) as were changes in Sequential Organ Failure Assessment scores over a 5-day monitoring period after enrollment. Angiotensin II was not associated with increased rates of kidney replacement therapy (odds ratio [OR], 1.39; 95% CI, 0.88-2.19; p = 0.158) or receipt of mechanical ventilation (OR, 1.50; 95% CI, 0.41-5.51; p = 0.539) after enrollment, and the rate of thrombotic events was similar between angiotensin II and control patients (OR, 1.02; 95% CI, 0.71-1.48; p = 0.912).ConclusionsIn patients with severe shock, angiotensin II was not associated with improved mortality or organ dysfunction and was not associated with an increased rate of adverse events.Copyright © 2023 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

17 keywords...

hide…